Form 4: Protagonist Therapeutics Director Waddill Exercises Options and Sells Shares

Director William D. Waddill exercised stock options and sold shares of Protagonist Therapeutics, Inc. on June 7, 2024, according to a Form 4 filing.

Summary

• William D. Waddill, a director of Protagonist Therapeutics, Inc., executed transactions involving the company's stock on June 7, 2024.
• Waddill exercised stock options to acquire 8,000 shares of common stock at a price of $12.88 per share.
• Simultaneously, Waddill sold 8,000 shares of common stock at $35 per share.
• Following these transactions, Waddill directly owns 12,000 shares of Protagonist Therapeutics common stock and 16,000 stock options.
• The sale of shares was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions are part of a pre-arranged plan, and there's no indication of a significant change in the director's outlook on the company.

Positives

• The exercise of stock options demonstrates the director's belief in the company's long-term value, as they chose to convert the options into shares.
• The director still holds 12,000 shares directly and options for 16,000 shares.

Negatives

• The sale of 8,000 shares, even under a pre-arranged plan, could be interpreted negatively by some investors.

Risks

• The market may react negatively to the sale of shares by a director, even if it's part of a pre-planned strategy.
• Continued sales by insiders could put downward pressure on the stock price.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Insider transactions are common in publicly traded companies, and are closely monitored by investors for signals about a company's prospects. Rule 10b5-1 plans are often used to allow insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• It is common for directors and officers of publicly traded companies to have stock option grants as part of their compensation packages.
• The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of insider trading when selling company stock.
• The size of the transaction is relatively small, suggesting it is part of a personal financial strategy rather than a major shift in sentiment.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they are interpreted.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely to be negligible.

Key Dates